Treprostinil (Orenitram, Remodulin, Tyvaso, Tyvaso DPI) coverage
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PHAR.199 alerts
Get alerted when Policy MDN.CP.PHAR.199 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, and coverage criteria for treprostinil formulations for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) for Meridian lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Treprostinil
Initial Therapy - PAH
Covered when ALL of the following are met
See Appendix B for calcium channel blocker regimens and Appendix D/E for classifications
Initial Therapy - PH-ILD
Covered when ALL of the following are met
Continued Therapy - PAH
Covered when ALL of the following are met
Approval duration: 12 months
Continued Therapy - PH-ILD
Covered when ALL of the following are met
Approval duration: 12 months
Other indications / Off-label guidance
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policies (for commercial: CP.CPA.09; for health insurance marketplace: HIM.PA.154; for Medicaid: CP.PMN.53) or other evidence of coverage documents.
Per the policy revision history, Flolan (epoprostenol) was removed from the step therapy sequence for pulmonary arterial hypertension because it is now classified as non‑preferred (NP).
Coding, Dose Limits, and Hemodynamic Thresholds
| No codes listed |
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required — document diagnosis, specialist involvement, and prior therapies
Prior authorization is required. The provider must document the diagnosis of PAH or PH-ILD, that the drug is prescribed by or in consultation with a cardiologist or pulmonologist, and prior therapies (including failure of a calcium channel blocker and, when applicable, failure of generic epoprostenol). For certain formulations, include dosing/titration or device-specific treatment plans as specified in the criteria.
- Diagnosis must be documented (PAH or PH-ILD as applicable).
- Prescribed by or in consultation with a cardiologist or pulmonologist.
- Document prior therapy failures (e.g., calcium channel blocker, generic epoprostenol when required).
- Include formulation-specific plans (titration plan for Orenitram; Remodulin pump/treatment details; inhaled dose limits for Tyvaso/Tyvaso DPI).
PA applies to treprostinil products — relevant HCPCS codes
Prior authorization applies to treprostinil products; reference HCPCS codes should be used for informational purposes when preparing PA submissions and claims.
Step therapy for PAH — CCB failure and trial of generic epoprostenol
For PAH, step therapy requires failure of a calcium channel blocker unless the member has inadequate response to acute vasodilator testing or contraindication/intolerable adverse effects; additionally, failure of generic epoprostenol for ≥ 3 consecutive months is required before treprostinil.
- Exceptions to calcium channel blocker requirement: inadequate response to acute vasodilator testing or contraindication/clinically significant adverse effects.
- Generic epoprostenol must have been used for at least 3 consecutive months unless contraindicated or intolerant.
Generic trial preference — require trial of generic treprostinil before brand Remodulin
Policy history requires trial of generic treprostinil prior to brand Remodulin when both brand and generic are non-preferred; generic redirection and preferencing decisions are reflected in prior revisions.
- If request is for brand Remodulin, member must use generic treprostinil unless contraindicated or adverse effects are experienced.
- Past revisions added requirement for trial of generic treprostinil when both brand and generic are non-preferred.
Required clinical documentation — submit office notes, labs, and treatment details
Submit supporting clinical documentation with the PA request, such as office chart notes, laboratory results, and other clinical information demonstrating that the member meets all approval criteria.
- Office or clinic notes documenting diagnosis, specialist involvement, and prior therapy trials.
- Relevant labs and hemodynamic data (e.g., right heart catheterization values when required).
- Formulation-specific documentation (titration plans, pump settings, cassette frequency) when applicable.
Submit titration and treatment plans — Orenitram and Remodulin requirements
When applicable, include a titration plan for Orenitram and a treatment plan for Remodulin detailing pump rate, dose, quantity (mL), and cassette change frequency as part of the PA submission.
- Orenitram: provide titration plan if titration is required.
- Remodulin: provide treatment plan with pump rate, dose, mL quantity, and frequency of cassette changes.
Denial risk — missing documentation may result in denial
Failure to provide the requested documentation (office notes, labs, or other clinical information) demonstrating that the approval criteria are met may result in denial of the request.
- Ensure all criteria are supported by submitted records; missing documentation can lead to denial.
Coding disclaimer — codes listed do not guarantee coverage
Inclusion or exclusion of HCPCS/CPT codes in this policy is informational only and does not guarantee coverage; claims may be denied if coding or coverage criteria are not met.
- Providers should use up-to-date professional coding guidance prior to claim submission.
Background and Clinical Context
Treprostinil is a prostacyclin analog available in multiple formulations—oral (Orenitram), parenteral (Remodulin), inhaled solution (Tyvaso), and inhalation powder (Tyvaso DPI)—with formulation‑specific dosing and administration requirements. It is FDA‑approved for treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Select inhaled formulations (Tyvaso and Tyvaso DPI) also have an indication for pulmonary hypertension associated with interstitial lung disease (WHO Group 3), and clinical trials for inhaled treprostinil were generally conducted on a background of endothelin receptor antagonists or phosphodiesterase‑5 inhibitors.
Definitions and Formulations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.